Navigation Links
NeurogesX to Present at Two February Investor Conferences
Date:2/8/2011

SAN MATEO, Calif., Feb. 8, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at two upcoming conferences in New York, New York: the 13th Annual BIO CEO & Investor Conference, to be held February 14-15, 2011 at the Waldorf-Astoria Hotel; and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference, to be held February 16-17, 2011 at The Roosevelt Hotel.

During the Leerink Swann Conference, Mr. DiTonno will also represent NeurogesX on a panel of executives from leading neurology/pain companies. Mr. DiTonno and Stephen Ghiglieri, SVP, COO and CFO, will be available to respond to questions and to participate in one-on-one meetings with investors attending both conferences.Event: 13th Annual BIO CEO & Investor ConferenceDate: Tuesday, February 15, 2011Time: 11:00 am ETPlace: The Waldorf-Astoria Hotel, New York, NY (Conrad Room, 4th floor) Event: Leerink Swann Hot Topics in Therapeutics Roundtable ConferenceDate: Thursday, February 17, 2011Time: 11:00 am ET (Neuro/Pain panel); 3:40 pm ET (presentation)Place: The Roosevelt Hotel, New York, NY (Terrace Ballroom, lobby level) Both presentations will be webcast live and archived for 90 days on the investor relations section of NeurogesX' website at www.neurogesx.com.

About NeurogesX, Inc. NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... Repligen Corporation,(Nasdaq: RGEN ) announced today that ... to evaluate the use of RG1068, synthetic human ... by magnetic resonance,imaging (MRI). This Phase 3 study ... approximately 250 patients will receive an,unenhanced MRI followed ...
... First-in-Class Treatment for Type 2 Diabetes -, ... company focused on the discovery and development of,proprietary ... today that it has dosed the first cohort ... of MBX-2982, a potential first-in-class treatment,for type 2 ...
Cached Medicine Technology:Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4Metabolex Initiates Phase 1 Trial of MBX-2982 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... 2014 Recently, Fancyflyingfox.com, an innovative company ... has announced its latest designs of 2014 mother ... new elegant outfits are offered with big discounts, up ... before October 30 can enjoy this special offer. ... strategies, it has become one of the leading brands ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... By Steven Reinberg HealthDay Reporter , ... reports of potentially hazardous food products were filed with ... first seven months of operation, the U.S. Food and ... requires manufacturers, processors, packers and distributors to immediately report ...
... , WEDNESDAY, July 28 (HealthDay News) -- A certain type ... disease and other neurological disorders, new research confirms. ... people violently act out their dreams during the rapid eye ... and related neurological disorders as much as a half century ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, July ... rheumatoid arthritis at bay, possibly because it dampens the ... may also protect people who already have the autoimmune ... actually isn,t a new concept. There have been other ...
... new study of mental health status and the use of ... Policy Research found that nearly one in five adults in ... needed help for a mental or emotional health problem. ... than 1 million, reported symptoms associated with serious psychological distress ...
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- The ... their 40s is due more to the technology itself than ... study. For years, experts have known that mammography,s performance ... and they,ve placed much of the blame on the notion ...
... heterosexual men,s hostility, while heterosexual men, gay men and ... Dr. Scott Keiller from Kent State University at Tuscarawas ... due to women,s unparalleled potential for gratifying, or frustrating, ... gatekeepers in men,s quests for sexual pleasure, patriarchal power ...
Cached Medicine News:Health News:FDA Cites Its Food Safety Web Site 2Health News:Sleep Disorder May Help Predict Parkinson's Decades Earlier 2Health News:Sleep Disorder May Help Predict Parkinson's Decades Earlier 3Health News:Could Drinking Help Thwart Rheumatoid Arthritis? 2Health News:Could Drinking Help Thwart Rheumatoid Arthritis? 3Health News:Nearly 1 in 5 Californians report need for mental health services, study finds 2Health News:Technology May Explain Mammogram's Poorer Performance in Younger Women 2Health News:Technology May Explain Mammogram's Poorer Performance in Younger Women 3Health News:A man with attitude 2
Freedom Cath® is a latex, self-adhering, one-piece catheter designed for everyday wear....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: